SEC Form 4 · accession 0001683168-16-000115
Rennova Health, Inc. · RNVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 17, 2016
Accepted (ET)
Sep 14, 2016 · 5:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000931059
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 17, 2016 | A | 333,334 | $0.30 | A | 344,234 | D | |
| Common StockF1 | Jul 25, 2016 | J | 333,334 | $0.30 | A | 755,261 | I | By: Alcimede LLC |
| Common StockF2 | Aug 5, 2016 | J | 1,171,667 | $0.30 | A | 1,926,928 | I | By: Alcimede LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common Stock | $0.30 | Jul 17, 2016 | A | 250,000 | A | Jul 17, 2016 | Jul 17, 2026 | Common Stock | 250,000 | 250,000 | D |
| Options to Purchase Common Stock | $0.30 | Jul 17, 2016 | A | 250,000 | A | Dec 31, 2016 | Jul 17, 2026 | Common Stock | 250,000 | 250,000 | D |
| Options to Purchase Common Stock | $0.30 | Jul 17, 2016 | A | 250,000 | A | Dec 31, 2017 | Jul 17, 2026 | Common Stock | 250,000 | 250,000 | D |
| Options to Purchase Common Stock | $0.30 | Jul 17, 2016 | A | 250,000 | A | Dec 31, 2018 | Jul 17, 2026 | Common Stock | 250,000 | 250,000 | D |
| Options to Purchase Common StockF3 | $0.30 | Jul 17, 2016 | A | 500,000 | A | — | Jul 17, 2026 | Common Stock | 500,000 | 500,000 | D |
| Options to Purchase Common StockF4 | $0.30 | Jul 17, 2016 | A | 500,000 | A | — | Jul 17, 2026 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Alcimede LLC received the shares in lieu of a $100,000 cash payment for services rendered.
- F2Alcimede LLC received the shares in exchange for the cancellation of outstanding debt.
- F3The options become first exercisable upon the Issuer attaining $75 million in gross revenue in any of the Issuer's three fiscal years from the date of grant through December 31, 2018.
- F4The options become first exercisable upon the Issuer attaining a $100 million market capitalization at any time during the three year period ending July 17, 2019.
Remarks
Exhibit List - Exhibit 99 - Joint Filer Information